Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial |
| |
| Authors: | Cho Sung Joon Yook Keunyoung Kim Borah Choi Tai Kiu Lee Kang Soo Kim Yong Woo Lee Ji Eun Suh Shinyoung Yook Ki Hwan Lee Sang-Hyuk |
| |
| Affiliation: | Department of Psychiatry, CHA Bundang Medical Center, CHA University School of Medicine, 351 Yatap-Dong, Bundang-Gu, Seongnam-Si, Kyounggi-Do 463-712, South Korea |
| |
| Abstract: | This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia. In an 8-week, double-blind clinical trial, we randomly assigned 21 stabilized outpatients with schizophrenia undergoing risperidone treatment to adjunctive treatment with either mirtazapine or a placebo. The mirtazapine group exhibited a statistically significant improvement in cognitive function, including vocabulary and immediate memory, and negative symptoms (as measured by negative symptom scales) and showed an adverse effect of 5.83 kg mean weight gain. This study suggests augmenting risperidone with mirtazapine can effectively improve both negative and some cognitive symptoms of schizophrenia.Research highlights? Mirtazapine enhances some cognitive symptoms of schizophrenia. ? Mirtazapine reduces negative symptoms of schizophrenia. |
| |
| Keywords: | CGI, Clinical Global Impressions scale K-WAIS, Korean-Wechsler Adult Intelligence Scale PANSS, Positive and Negative Symptom Scale SANS, Scale for the Assessment of Negative Symptoms |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
